Clinical trial
Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
NCT01429610 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia
- Lead sponsor
- Asan Medical Center
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 30, 2011
- Completion date
- January 1, 2019
- Enrollment
- 78 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.